Ratings by Raymond James (Steven Seedhouse)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/28/2026 | Korro Bio Inc. | KRRO | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/11/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/13/2025 | Korro Bio Inc. | KRRO | Downgrade | Market Perform (Outperform) |
32.80 (11.18) |
-65.91% | Details | |
| 9/9/2025 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Korro Bio Inc. | KRRO | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/1/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Inflarx NV | IFRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/9/2025 | Apellis Pharmaceuticals | APLS | Downgrade | Outperform (Strong Buy) |
17.81 (20.07) |
12.69% | Details | |
| 3/14/2025 | ProQR Therapeutics N.V. | PRQR | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/3/2025 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/13/2025 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/11/2024 | Q32 Bio Inc. | QTTB | Downgrade | Outperform (Strong Buy) |
22.67 (4.70) |
-79.27% | Details | |
| 11/4/2024 | Editas Medicine | EDIT | Downgrade | Market Perform (Outperform) |
2.91 (2.00) |
-31.27% | Details | |
| 10/29/2024 | ProQR Therapeutics N.V. | PRQR | Upgrade | Strong Buy (Outperform) |
3.31 (1.78) |
-46.22% | Details | |
| 10/24/2024 | Q32 Bio Inc. | QTTB | New Coverage | Strong Buy (N/A) |
46.70 (22.67) |
-51.46% | Details | |
| 10/21/2024 | Korro Bio Inc. | KRRO | New Coverage | Strong Buy (N/A) |
80.04 (32.80) |
-59.02% | Details | |
| 10/16/2024 | WAVE Life Sciences | WVE | Upgrade | Strong Buy (Outperform) |
8.56 (13.12) |
53.27% | Details | |
| 7/8/2024 | Gilead Sciences | GILD | Upgrade | Outperform (Market Perform) |
66.59 (143.93) |
116.14% | Details | |
| 3/12/2024 | NGM Biopharmaceuticals | NGM | Downgrade | Market Perform (Outperform) |
1.53 (1.54) |
0.65% | Details | |
| 3/6/2024 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2024 | CymaBay Therapeutic | CBAY | Downgrade | Market Perform (Strong Buy) |
25.69 (32.48) |
26.43% | Details | |
| 10/18/2023 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/28/2023 | Dianthus Therapeutics | DNTH | New Coverage | Outperform (N/A) |
13.31 (65.20) |
389.86% | Details | |
| 8/29/2023 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/21/2023 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/15/2023 | Zura Bio Ltd. | ZURA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/4/2023 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/31/2023 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/17/2023 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/5/2023 | WAVE Life Sciences | WVE | New Coverage | Outperform (N/A) |
3.56 (13.12) |
268.54% | Details | |
| 6/26/2023 | Zura Bio Ltd. | ZURA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/12/2023 | Editas Medicine | EDIT | Upgrade | Outperform (Market Perform) |
9.67 (2.00) |
-79.32% | Details | |
| 5/24/2023 | Zura Bio Ltd. | ZURA | New Coverage | Strong Buy (N/A) |
5.35 (6.97) |
30.28% | Details | |
| 5/17/2023 | Intercept Pharmaceuticals | ICPT | Downgrade | Market Perform (Outperform) |
16.21 (19.00) |
17.21% | Details | |
| 5/5/2023 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/28/2023 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2023 | VBI Vaccines | VBIV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2023 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/9/2023 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/27/2023 | Dyne Therapeutics | DYN | Upgrade | Strong Buy (Outperform) |
12.30 (14.86) |
20.81% | Details | |
| 2/23/2023 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2023 | Jounce Therapeutics | JNCE | Downgrade | Market Perform (Outperform) |
1.04 (1.88) |
80.77% | Details | |
| 2/22/2023 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/19/2023 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2023 | CymaBay Therapeutic | CBAY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/10/2023 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/22/2022 | ProQR Therapeutics N.V. | PRQR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2022 | Avidity Biosciences | RNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/18/2022 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/11/2022 | VBI Vaccines | VBIV | Downgrade | Outperform (Strong Buy) |
0.61 (0.07) |
-88.52% | Details | |
| 11/11/2022 | Jounce Therapeutics | JNCE | Downgrade | Outperform (Strong Buy) |
1.99 (1.88) |
-5.53% | Details | |
| 11/10/2022 | Inflarx NV | IFRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/9/2022 | Avidity Biosciences | RNA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/4/2022 | NGM Biopharmaceuticals | NGM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Dyne Therapeutics | DYN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/25/2022 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/18/2022 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/18/2022 | NGM Biopharmaceuticals | NGM | Downgrade | Outperform (Strong Buy) |
11.55 (1.54) |
-86.67% | Details | |
| 9/16/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/30/2022 | Jounce Therapeutics | JNCE | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/12/2022 | Landos Biopharma | LABP | Downgrade | Market Perform (Outperform) |
1.23 (22.93) |
1764.23% | Details | |
| 8/12/2022 | ProQR Therapeutics N.V. | PRQR | Upgrade | Outperform (Market Perform) |
0.84 (1.78) |
111.9% | Details | |
| 8/10/2022 | Arcturus Therapeutics | ARCT | Downgrade | Underperform (Market Perform) |
21.02 (7.11) |
-66.18% | Details | |
| 8/9/2022 | VBI Vaccines | VBIV | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/9/2022 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/4/2022 | ChemoCentryx | CCXI | Downgrade | Market Perform (Strong Buy) |
24.11 (10.16) |
-57.86% | Details | |
| 7/12/2022 | Dyne Therapeutics | DYN | New Coverage | Outperform (N/A) |
9.02 (14.86) |
64.75% | Details | |
| 7/12/2022 | Avidity Biosciences | RNA | New Coverage | Strong Buy (N/A) |
17.07 (14.82) |
-13.18% | Details | |
| 5/18/2022 | Galmed Pharmaceuticals | GLMD | Downgrade | Market Perform (Outperform) |
0.58 (0.66) |
13.79% | Details | |
| 5/13/2022 | Landos Biopharma | LABP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2022 | Inflarx NV | IFRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/9/2022 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/6/2022 | Jounce Therapeutics | JNCE | Upgrade | Strong Buy (Outperform) |
5.22 (1.88) |
-63.98% | Details | |
| 5/5/2022 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/2/2022 | Galmed Pharmaceuticals | GLMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2022 | Inflarx NV | IFRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/25/2022 | Landos Biopharma | LABP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2022 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/8/2022 | VBI Vaccines | VBIV | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/1/2022 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/11/2022 | ProQR Therapeutics N.V. | PRQR | Downgrade | Market Perform (Strong Buy) |
5.64 (1.78) |
-68.44% | Details | |
| 2/1/2022 | ProQR Therapeutics N.V. | PRQR | New Coverage | Strong Buy (N/A) |
5.20 (5.64) |
8.46% | Details | |
| 1/31/2022 | Arcturus Therapeutics | ARCT | Upgrade | Market Perform (Underperform) |
22.30 (7.11) |
-68.12% | Details | |
| 1/12/2022 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/11/2022 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/11/2021 | CymaBay Therapeutic | CBAY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/9/2021 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2021 | Inflarx NV | IFRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2021 | NGM Biopharmaceuticals | NGM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/4/2021 | Jounce Therapeutics | JNCE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2021 | Inflarx NV | IFRX | Upgrade | Strong Buy (Outperform) |
2.86 (1.82) |
-36.36% | Details | |
| 10/8/2021 | ChemoCentryx | CCXI | Upgrade | Strong Buy (Outperform) |
19.60 (24.11) |
23.01% | Details | |
| 9/30/2021 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/28/2021 | ChemoCentryx | CCXI | Maintain | Outperform (N/A) |
|
Details | ||
| 9/14/2021 | Jounce Therapeutics | JNCE | Upgrade | Outperform (Market Perform) |
6.35 (1.88) |
-70.39% | Details | |
| 9/13/2021 | NGM Biopharmaceuticals | NGM | Upgrade | Strong Buy (Outperform) |
21.25 (1.54) |
-92.75% | Details | |
| 9/8/2021 | Kadmon Holdings | KDMN | Downgrade | Market Perform (Outperform) |
5.30 (9.50) |
79.25% | Details | |
| 8/12/2021 | Arcturus Therapeutics | ARCT | Downgrade | Underperform (Market Perform) |
50.58 (22.30) |
-55.91% | Details | |
| 8/10/2021 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/30/2021 | Landos Biopharma | LABP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2021 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/7/2021 | Biogen | BIIB | Upgrade | Market Perform (Underperform) |
286.14 (234.72) |
-17.97% | Details | |
| 5/24/2021 | NGM Biopharmaceuticals | NGM | Downgrade | Outperform (Strong Buy) |
28.38 (21.25) |
-25.12% | Details | |
| 5/13/2021 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2021 | ChemoCentryx | CCXI | Downgrade | Outperform (Strong Buy) |
27.49 (19.60) |
-28.7% | Details | |
| 5/7/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2021 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2021 | NGM Biopharmaceuticals | NGM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/5/2021 | Kadmon Holdings | KDMN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2021 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/1/2021 | Landos Biopharma | LABP | New Coverage | Outperform (N/A) |
12.99 (22.93) |
76.52% | Details | |
| 2/26/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2021 | Editas Medicine | EDIT | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/11/2021 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/7/2021 | Alexion Pharmaceuticals | ALXN | Downgrade | Market Perform (Outperform) |
157.76 (182.01) |
15.37% | Details | |
| 1/7/2021 | Editas Medicine | EDIT | Downgrade | Market Perform (Outperform) |
80.54 (2.00) |
-97.52% | Details | |
| 12/29/2020 | Arcturus Therapeutics | ARCT | Downgrade | Market Perform (Outperform) |
98.13 (7.11) |
-92.75% | Details | |
| 11/13/2020 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/10/2020 | Arcturus Therapeutics | ARCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Intercept Pharmaceuticals | ICPT | Upgrade | Outperform (Market Perform) |
28.15 (19.00) |
-32.5% | Details | |
| 11/6/2020 | Kadmon Holdings | KDMN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | CymaBay Therapeutic | CBAY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2020 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2020 | Jounce Therapeutics | JNCE | Downgrade | Market Perform (Strong Buy) |
8.32 (1.88) |
-77.4% | Details | |
| 10/29/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2020 | Apellis Pharmaceuticals | APLS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/19/2020 | 89bio Inc. | ETNB | New Coverage | Strong Buy (N/A) |
23.73 (14.84) |
-37.46% | Details | |
| 9/9/2020 | Mirum Pharamceuticals | MIRM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/27/2020 | VBI Vaccines | VBIV | Upgrade | Strong Buy (Outperform) |
3.28 (0.07) |
-97.87% | Details | |
| 8/11/2020 | CymaBay Therapeutic | CBAY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/11/2020 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/11/2020 | Arcturus Therapeutics | ARCT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | Kadmon Holdings | KDMN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | Mirum Pharamceuticals | MIRM | Upgrade | Strong Buy (Outperform) |
22.37 (86.21) |
285.38% | Details | |
| 8/7/2020 | Mimecast Limited | MIME | Upgrade | Strong Buy (Outperform) |
45.97 (79.92) |
73.85% | Details | |
| 7/31/2020 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2020 | Arcturus Therapeutics | ARCT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/23/2020 | CymaBay Therapeutic | CBAY | Upgrade | Strong Buy (Outperform) |
3.51 (32.48) |
825.36% | Details | |
| 7/22/2020 | VBI Vaccines | VBIV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/16/2020 | Arcturus Therapeutics | ARCT | New Coverage | Outperform (N/A) |
54.00 (7.11) |
-86.83% | Details | |
| 6/17/2020 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2020 | Intercept Pharmaceuticals | ICPT | Downgrade | Outperform (Strong Buy) |
91.69 (19.00) |
-79.28% | Details | |
| 5/21/2020 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/21/2020 | Kadmon Holdings | KDMN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2020 | Kadmon Holdings | KDMN | New Coverage | Outperform (N/A) |
4.42 (5.30) |
19.91% | Details | |
| 5/18/2020 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/15/2020 | Galmed Pharmaceuticals | GLMD | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2020 | NGM Biopharmaceuticals | NGM | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/12/2020 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/12/2020 | CymaBay Therapeutic | CBAY | Upgrade | Outperform (Market Perform) |
1.78 (3.51) |
97.19% | Details | |
| 5/8/2020 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2020 | Gilead Sciences | GILD | Downgrade | Market Perform (Outperform) |
83.14 (66.59) |
-19.91% | Details | |
| 4/30/2020 | Inflarx NV | IFRX | Upgrade | Outperform (Market Perform) |
5.80 (2.86) |
-50.69% | Details | |
| 4/29/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2020 | NGM Biopharmaceuticals | NGM | New Coverage | Strong Buy (N/A) |
12.45 (28.38) |
127.95% | Details | |
| 4/1/2020 | Apellis Pharmaceuticals | APLS | New Coverage | Strong Buy (N/A) |
28.68 (17.81) |
-37.9% | Details | |
| 3/25/2020 | Jounce Therapeutics | JNCE | Upgrade | Strong Buy (Outperform) |
4.33 (8.32) |
92.15% | Details | |
| 3/13/2020 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2020 | Bellicum Pharmaceuticals | BLCM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2020 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/27/2020 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2020 | Gilead Sciences | GILD | Downgrade | Outperform (Strong Buy) |
66.36 (143.93) |
116.89% | Details | |
| 1/31/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/15/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2019 | Audentes Therapeutics | BOLD | Downgrade | Market Perform (Outperform) |
28.61 (1.13) |
-96.05% | Details | |
| 11/26/2019 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/26/2019 | CymaBay Therapeutic | CBAY | Downgrade | Market Perform (Strong Buy) |
5.55 (32.48) |
485.23% | Details | |
| 11/14/2019 | VBI Vaccines | VBIV | New Coverage | Outperform (N/A) |
0.56 (3.28) |
485.71% | Details | |
| 11/1/2019 | Intellia Therapeutics | NTLA | Upgrade | Outperform (Market Perform) |
11.77 (13.44) |
14.19% | Details | |
| 10/25/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/21/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/30/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/23/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/23/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/12/2019 | Mirum Pharamceuticals | MIRM | New Coverage | Outperform (N/A) |
14.77 (86.21) |
483.68% | Details | |
| 8/7/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/31/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/29/2019 | Bellicum Pharmaceuticals | BLCM | New Coverage | Outperform (N/A) |
1.47 (0.62) |
-57.82% | Details | |
| 7/29/2019 | Audentes Therapeutics | BOLD | New Coverage | Outperform (N/A) |
38.57 (28.61) |
-25.82% | Details | |
| 7/29/2019 | Ra Pharma | RARX | Downgrade | Market Perform (Strong Buy) |
35.96 (48.00) |
33.48% | Details | |
| 7/23/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/23/2019 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2019 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/25/2019 | Acer Therapeutics | ACER | Downgrade | Market Perform (Outperform) |
19.28 (0.90) |
-95.33% | Details | |
| 6/12/2019 | CymaBay Therapeutic | CBAY | Upgrade | Strong Buy (Outperform) |
11.09 (32.48) |
192.88% | Details | |
| 6/6/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/5/2019 | Inflarx NV | IFRX | Downgrade | Market Perform (Outperform) |
37.29 (0.97) |
-97.4% | Details | |
| 5/29/2019 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2019 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2019 | Ra Pharma | RARX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/9/2019 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2019 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/3/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/26/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/23/2019 | ChemoCentryx | CCXI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/23/2019 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2019 | Ra Pharma | RARX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2019 | Alexion Pharmaceuticals | ALXN | New Coverage | Outperform (N/A) |
139.75 (182.01) |
30.24% | Details | |
| 4/10/2019 | Biogen | BIIB | New Coverage | Market Perform (N/A) |
239.74 (329.01) |
37.24% | Details | |
| 3/8/2019 | Ra Pharma | RARX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/28/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/15/2019 | Acer Therapeutics | ACER | New Coverage | Outperform (N/A) |
24.35 (19.28) |
-20.82% | Details | |
| 2/12/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/5/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/4/2019 | Intercept Pharmaceuticals | ICPT | Upgrade | Strong Buy (Outperform) |
116.62 (91.69) |
-21.38% | Details | |
| 1/24/2019 | Gilead Sciences | GILD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/2/2018 | Intercept Pharmaceuticals | ICPT | Downgrade | Outperform (Strong Buy) |
126.36 (116.62) |
-7.71% | Details |
